The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
(For example, paragangliomas of the adrenal medulla are pheochromocytomas, and paragangliomas of the carotid bifurcation are carotid body tumors.) Lesions may occur in multiples along the extra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback